A crossover is a design or process in which two things switch places. The term appears most often in two contexts: clinical trial design, where participants receive multiple treatments in sequence, and genetics, where chromosomes exchange segments of DNA during cell division. Both meanings share the same core idea of swapping, but they apply to very different fields.
Crossover in Clinical Trials
In a crossover trial, every participant receives both the treatment being tested and the comparison (often a placebo or existing drug), just in a different order. Participants are randomly split into two groups. One group gets Treatment A first, then Treatment B. The other group gets Treatment B first, then Treatment A. This is called an AB/BA design, and it’s the simplest and most common version.
The key advantage is that each person serves as their own control. Instead of comparing one group of people against a different group, researchers compare each individual’s response to Treatment A with that same individual’s response to Treatment B. This eliminates a huge source of noise in medical research: the natural differences between people’s bodies, genetics, and lifestyles. Because of this, crossover trials can produce reliable results with far fewer participants than a standard two-group trial would need.
Why the Washout Period Matters
Between the two treatment phases, researchers build in a break called a washout period. During this gap, participants either stop all treatment or return to their usual routine so the first treatment’s effects can fully clear the body. In one well-known crossover study comparing butter and margarine diets in people with high cholesterol, each diet phase lasted six weeks, separated by a five-week washout where participants ate normally.
If the washout is too short, the first treatment can bleed into the second phase and distort the results. This is called a carryover effect, and it’s the single biggest threat to crossover trial validity. Carryover can be biological, meaning the drug hasn’t fully left the body, or behavioral, meaning the first treatment changed a participant’s habits or expectations in ways that persist. A washout period can address the biological kind, but the behavioral kind is harder to eliminate. When carryover goes undetected, it can either inflate or mask the true difference between treatments, leading to misleading conclusions either way.
Where Crossover Designs Are Used
The U.S. Food and Drug Administration considers crossover trials the standard approach for bioequivalence studies, which are the tests used to confirm that a generic drug works the same way as the brand-name version. Because each subject serves as their own control, the comparison between two very similar formulations is far more precise than it would be in a traditional parallel trial.
Crossover designs work best for stable, chronic conditions like asthma, high blood pressure, or chronic pain, where the underlying disease doesn’t change much over the course of the study. They’re a poor fit for conditions that resolve on their own (like an acute infection) or situations where the first treatment could permanently alter the disease, since there would be no meaningful “baseline” to return to before the second phase.
Drawbacks of the Crossover Approach
Because participants must complete two or more treatment phases plus washout periods, crossover trials take longer than parallel trials. That extended timeline leads to higher dropout rates. Attrition rates of 5% to 10% are common, and they can climb as high as 25%. Every participant who drops out loses both data points (their response to each treatment), which erodes the study’s statistical power more than a single dropout would in a parallel design.
The longer duration also limits crossover studies to treatments with relatively short-acting effects. A drug that takes months to reach full effect or months to wash out of the body makes the trial impractically long and increases the risk that the disease itself changes between periods.
Crossover in Genetics
In biology, crossing over refers to the physical exchange of DNA segments between paired chromosomes during the formation of egg and sperm cells. It happens during meiosis, the type of cell division that produces reproductive cells with half the usual number of chromosomes.
Here’s how it works: before a cell divides, matching chromosomes (one inherited from each parent) line up side by side. At certain points along their length, the strands break and reconnect with the opposite chromosome, swapping sections of genetic material. The result is chromosomes that carry a new combination of genes, different from either parent’s original version.
How Often Crossing Over Happens
Crossing over isn’t a rare event. In humans, an average of about 38 crossover events occur across the 22 non-sex chromosome pairs during the formation of a single egg cell, and roughly 24 during sperm cell formation. That means every egg or sperm you produce carries dozens of reshuffled chromosome segments, each one a unique patchwork of your parents’ DNA.
This reshuffling is one of the main engines of genetic diversity. It’s the reason siblings who share the same two parents can look and function so differently from one another. Without crossing over, the only variation between offspring would come from which whole chromosomes they happened to inherit. Crossing over breaks that limitation by creating entirely new gene combinations on each chromosome, vastly expanding the range of possible genetic outcomes in every generation.